我们报道了在两个中心接受未经处理的半相合性（HAPLO）骨髓移植（BMT）的634名患者。诊断为急性髓系白血病（AML）（n = 251）、急性淋巴细胞白血病（ALL）（n = 107）、骨髓增生异常综合征和骨髓纤维化（MDS + MF）（n = 125）和慢性淋巴增生性疾病（n = 151）。中位年龄为52岁（16-74岁）。移植物抗宿主病（GvHD）预防为从第0天开始静脉注射环孢素（CSA），从第+1天开始口服麦考酚酯，从第+3+5天开始术后环磷酰胺（PTCY）。23名患者（3.6％）出现原发移植物失败；其中17/23（74％）通过第二次HAPLO移植物获救，一年后仍然存活。急性GvHD II-IV级的累积发生率为29％，III-IV级为3％；中度重度慢性GvHD的累积发生率为23％：年龄较大的供体和患者是急性和慢性GvHD的重要预测因子。2年总非复发性死亡率（NRM）为19％：<40岁、41-60和> 60岁的患者分别为8％、21％和30％。在5年内，急性白血病初次缓解患者的无病生存率为64％，急性白血病CR2的无病生存率为51％，急性白血病晚期患者的无病生存率为25％，MDS / MPN的无病生存率为49％。我们证实，相对较多的患者中，未经处理的HAPLO BMT与+3+5天的PTCY相结合，尤其是在髓毒性清除方案后，跟随原发移植物失败和III-IV级GvHD的发生率较低；中度重度慢性GvHD为23％，2年NRM为19％；5年DFS受患者基础疾病缓解状况的影响。版权所有©2022 Elsevier Ltd。

We report 634 patients who underwent unmanipulated haploidentical (HAPLO) bone marrow transplantation (BMT) in two Centers. The diagnosis was acute myeloid leukemia (AML) (n = 251), acute lymphoblastic leukemia (ALL)(n = 107), myelodysplastic syndrome and myelofibrosis (MDS + MF) (n = 125) and chronic lymphoproliferative disorders (n = 151). Median age was 52 years (16-74). Graft versus host disease (GvHD) prophylaxis was intravenous cyclosporin (CSA) starting on day 0, oral mycophenolate on day +1, and post-transplant cyclophosphamide (PTCY) on days +3 + 5. Primary graft failure was seen in 23 patients (3,6%); 17 /23 (74%) were rescued with second HAPLO graft, and were alive at one year. The cumulative incidence of acute GvHD grade II-IV was 29% and 3% for grade III-IV; the cumulative incidence of moderate severe chronic GvHD was 23%: older donor and patients age were significant predictors of both acute and chronic GvHD. The overall non relapse mortality (NRM) at 2 years was 19%: 8%, 21% and 30% in patients aged <40, 41-60 > 60 years. Disease free survival (DFS) at 5 years was 64% for acute leukemia in first remission, 51% for acute leukemia CR2, 25% for acute leukemia advanced disease and 49% for MDS/MPN. We confirm, on a relatively large number of patients, that unmanipulated HAPLO BMT with PTCY on days +3 + 5, mostly after a myeloablative conditioning regimen, is followed by a low incidence of graft failure and grade III-IV GvHD; moderate severe chronic GvHD is 23% and NRM at 2 years 19%; 5 year DFS is influenced by remission status of the underlying disease.Copyright © 2022 Elsevier Ltd. All rights reserved.